

Multiple Sclerosis Injectables

Phone: (877)-246-9104 Fax: (800) 783-9146

www.biotekrx.com PATIENT INFORMATION PRESCRIBER INFORMATION Patient Name: Prescriber Name: Address: State License: NPI#: City, State, Zip: Phone: DEA: 2nd Phone: Phone: Address: DOB: Gender: ☐ Male ☐ Female City, State, Zip: Date: Contact Person: Weight: INSURANCE INFORMATION: Copy and attach the front and back of insurance and prescription card(s) Prescription Card: Name of Insurer: ______ ID#_____ BIN: _____ Group: ____ Primary Insurance: Name of Insurer: ID# BIN: PCN: Group: Secondary Insurance: Name of Insurer: ___ PCN: ID# BIN: Group: STATEMENT OF MEDICAL NECESSITY Diagnosis: Patient Evaluation: • Has patient been treated for this condition previously? \Box Yes \Box No ☐ Multiple Sclerosis 340 ☐ Other: ___ Medications failed: ___ Medical Assessment: (Type of MS): Is patient currently on therapy? ☐ Yes □ No ☐ Primary Progressive ☐ Secondary Progressive Type/Medication(s): ___ □ Relapsing-Remitting • Will patient discontinue the above medication(s) before starting the new ☐ Other: □ Allergies: ___ Other current medications: Strength/Formulation Refills Directions Medication □ Avonex vials □ 30 mcg ☐ IM weekly □ Avonex prefilled syringes ☐ Alternate dosing: _____ □ Avonex pen □ Betaseron ☐ SQ every other day □ 0.3 mg □ Alternate dosing: _ □ Rebif Starter Pak 22 mcg Titration Schedule 44 mcg Titration Schedule ☐ Week 1-2: 4.4 mcg (0.1 mL) SQ TIW ☐ Week 1-2: 8.8 mcg (0.1 mL) SQ TIW ☐ Week 3-4: 11 mcg (0.25mL) SQ TIW ☐ Week 3-4: 22 mcg (0.25 mL) SQ TIW ☐ Week 5+: 2 2 mcg (0.5 mL) SQ TIW ☐ Week 5+: 44 mcg (0.5 mL) SQ TIW □ Rebif ☐ 22 mcg Maintenance ☐ TIW (48 hours apart) ☐ 44 mcg Maintenance ☐ Alternate dosing: □ 0.25 mg injected subcutaneously every other day □ Extavia □ 0.3 mg

By signing below, I authorize BioTek reMEDys to collect my health condition information, prescription information from my doctor, healthcare provider, health insurer, or pharmacist in order to ensure its accuracy and completeness, to communicate to the patient support program of the pharmaceutical manufacturer (the program); and contact my insurer, other potential funding sources, social workers, patient advocacy organizations, and patient assistance programs on my behalf to determine if I am eligible for assistance. I hereby authorize my doctor, healthcare provider, health insurer, or pharmacist to provide my health condition, prescription information to BioTek reMEDys, and to the program. I understand that I may revoke this authorization at any time by sending a letter to BioTek reMEDys at BioTek reMEDys at 7227 Fannin Street Ste #103, Houston, TX 77030.

☐ Alternate dosing:

Prescriber's Signature: ______ Date: ______

[Substitution Allowed] Date: ______ Date: ______

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation.

If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited.

If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

Fax completed form to: (800) 783-9146 - Thank you for using BioTek reMEDys®

□ Other